XPO1 and neoplasm: Further validation of PPARG’s effect on this pathway was established through immunoblot of tumour lysates probing for PPARG, AKT3, PGC1α, CRM1 and VDAC1 (Fig. 2K and Supplementary Fig. 2B, C).